ArQule Announces Management Team Changes
March 15 2019 - 7:00AM
Business Wire
ArQule, Inc. (Nasdaq: ARQL) today announced that Robert
Weiskopf, Senior Vice President, Chief Financial Officer and
Treasurer, has decided to retire effective March 29 of this year.
In conjunction with Mr. Weiskopf’s departure, ArQule is naming Marc
Schegerin, MD as Chief Financial Officer and Head of Strategy,
effective as of Mr. Weiskopf’s retirement. Dr. Schegerin joined
ArQule in May 2018 and most recently served as Senior Vice
President, Head of Strategy, Finance and Communication.
“Rob has played a key role at ArQule throughout his impressive
twelve-year tenure and built a first-class finance organization. I
want to thank him for his many contributions and wish him the best
in his future endeavors,” said Paolo Pucci, Chief Executive
Officer.
“Marc brings a wealth of relevant experience from both industry
and healthcare investment banking and has played a central role in
multiple key initiatives at ArQule since joining the Company last
year. I am delighted to have Marc assume the role of CFO and look
forward to partnering with him as we progress our pipeline of
novel, small molecule kinase inhibitors in both cancer and rare
diseases,” continued Mr. Pucci.
Dr. Schegerin joined ArQule in May 2018 as Senior Vice
President, Head of Corporate Strategy, Finance and Communication
from Citigroup where he served as a Healthcare Investment Banking
Director. Prior to Citigroup, Dr. Schegerin held healthcare
investment banking positions at Merrill Lynch as Vice President and
at Goldman Sachs. Dr. Schegerin also served in multiple industry
roles, including Biogen and Sage Therapeutics. He received his M.D.
from Dartmouth Medical School and M.B.A. from the Tuck School of
Business at Dartmouth.
About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop
and commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, planned to initiate registrational trial
cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in
combination with the hormonal therapy, anastrozole, in patients
with advanced endometrial cancer; ARQ 751, a next generation highly
potent and selective AKT inhibitor, in phase 1 for patients with
AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in a registrational trial for iCCA in
collaboration with Basilea and Sinovant. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190315005034/en/
Corporate Contact:Kathleen FarrenInvestor Relations
&Executive Assistant to the CFOir@arqule.com
Media Contact:Cait Williamson, Ph.D.LifeSci Public
Relations (646) 751-4366cait@lifescipublicrelations.com
www.ArQule.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Aug 2024 to Sep 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Sep 2023 to Sep 2024